It supports cellular energy, which may help with fatigue, recovery, and training consistency
Srivatsan R, Das S, Gadde R, Manoj-Kumar K, Taduri S, Rao N, et al
What This Means for Patients These findings suggest that GLP-1 receptor agonists may offer benefits beyond blood sugar control, potentially helping to lower the risk of epilepsy in people with Type 2 diabetes
However, systematic reviews have shown that supplementation with vitamin D does not reduce high blood pressure or lower the risk of heart disease
Meet with a licensed healthcare provider online and learn whether peptide therapy may be appropriate for your recovery, wellness, healthy aging, or body composition goals
Clarivates Drugs to Watch 2026 report highlights Eli Lillys late-stage cardiometabolic candidates orforglipron and retatrutide as the clear standouts in an obesity and diabetes market projected to reach $150 billion by 2035